Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation.
Ontology highlight
ABSTRACT: Dexmedetomidine (DEX) is an anesthetic that is widely used in the clinic, and it has been reported to exhibit paradoxical effects in the progression of multiple solid tumors. In this study, we sought to explore the mechanism by which DEX regulates hepatocellular carcinoma (HCC) progression underlying liver fibrosis. We determined the effects of DEX on tumor progression in an orthotopic HCC mouse model of fibrotic liver. A coculture system and a subcutaneous xenograft model involving coimplantation of mouse hepatoma cells (H22) and primary activated hepatic stellate cells (aHSCs) were used to study the effects of DEX on HCC progression. We found that in the preclinical mouse model of liver fibrosis, DEX treatment significantly shortened median survival time and promoted tumor growth, intrah
SUBMITTER: Chen P
PROVIDER: S-EPMC8080602 | biostudies-literature | 2020 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA